Written by NHS legal defence spending is not a side issue. It is part of the accountability system for patient harm, staff disputes and whistleblowing cases. The key question is not whether the NHS should ever defend claims. It is whether taxpayers can see clearly when public money is being used to resolve harm, and when it is being used to protect institutions from scrutiny.
Publication snapshot
- The article separates overall clinical-negligence cost from claimant legal costs, NHS defence costs and legal-services framework value.
- The £2.6 billion figure and the £772 million framework figure do not measure the same thing.
- The central concern is transparency: how legal spend is allocated, who receives it, and what outcomes it produces.
- Firm-by-firm allegations about tactics or dominance should not be published as findings without procurement data and right-of-reply material.
- The reform route is granular reporting, independent oversight and a stricter ethical approach to whistleblowing and patient-safety disputes.
Why NHS legal defence spending matters
The NHS’s legal defence spending raises a basic public-accountability question: how much public money is being spent resolving harm, and how much is being spent defending institutions from the consequences of that harm?
Legal advice is necessary in complex clinical negligence, employment and liability claims. The NHS is entitled to defend weak or disputed claims. Clinicians, managers and public bodies are entitled to fair process where allegations are contested.
The concern is different. It is whether the system is transparent enough to show when legal spending protects patient safety and fair resolution, and when it mainly protects institutional reputation.
The £2.6 billion and £772 million figures are different things
The figures are often difficult to compare because they measure different parts of the system. A headline clinical-negligence total can include compensation, claimant legal costs and NHS defence legal costs. A legal-services framework is different: it is a procurement route through which panel law firms can be instructed.
The £2.6 billion figure refers to the wider cost of clinical-negligence payments in 2022/23. That total is driven primarily by damages and compensation, particularly in severe-injury cases where future care, loss of earnings, accommodation and lifelong support may be involved.
Within that wider total, claimant legal costs are a separate category. The draft figure of £490.9 million for 2022/23 should be treated as claimant-side legal cost, not money paid to NHS panel firms.
The defence-cost figure is different again. The draft figure of £158.8 million for 2022/23 describes NHS-side legal defence expenditure for that year. That is the figure most directly relevant to the question of what is being spent defending claims.
The £772 million figure is different again. It is presented as the value of NHS Resolution’s legal-services framework for 2022 to 2025. A framework value does not necessarily mean the same amount has already been spent. It is an authorised contracting envelope through which legal services can be procured over time.
Includes the wider cost of resolving claims, usually dominated by compensation and damages in serious injury cases.
Represents a procurement mechanism for instructing panel firms, not the whole financial burden of resolving claims.
The panel model needs public scrutiny
NHS Resolution’s panel model concentrates a large volume of healthcare litigation work among pre-approved firms. That can produce consistency, institutional memory and specialist expertise. Clinical negligence cases can be highly technical, and employment or liability claims may require experienced advisers.
A panel model is not inherently improper. The public question is whether the system gives enough visibility over spend, allocation, strategy and outcomes. Where large public contracts are used to defend claims involving patient harm, whistleblowing, staff detriment or governance failure, there should be a clear audit trail.
The firms named in public discussion include large healthcare and defendant litigation practices. It would be unsafe to treat broad claims about individual firms’ tactics, regional dominance or case allocation as findings without procurement documents, case data and right-of-reply material.
The stronger critique is structural: the panel model should be transparent enough that firm-level spend, case type and outcome can be scrutinised without relying on inference, screenshots or partial procurement material.
How opacity develops
-
1
Large framework contracts create the appearance of controlled procurement.
-
2
Individual case spend is spread across firms, counsel, experts, trust resource and internal management time.
-
3
Public reporting aggregates figures rather than showing case type, firm spend and outcome.
-
4
Taxpayers cannot see whether litigation strategy supports learning or mainly protects reputation.
The hidden cost problem
A procurement framework can make spending look controlled. It does not, by itself, show whether the underlying litigation culture is proportionate. A framework can rationalise instruction of firms while leaving open questions about duplication, counsel fees, expert evidence, local trust involvement and internal management costs.
A contested matter may involve trust staff time, internal governance meetings, disclosure work, external solicitors, barristers, experts, mediation, insurer input, senior management sign-off and communications advice.
This matters because the true cost of legal defence is rarely captured by a single headline number. If reporting does not distinguish damages, claimant costs, defence solicitors, counsel, experts, in-house teams and local trust resource, scrutiny remains incomplete.
Non-clinical claims and whistleblowing disputes
Non-clinical claims require separate scrutiny. Clinical negligence litigation is usually about compensating patients or families after alleged harm. Non-clinical disputes may include employment, whistleblowing, discrimination, governance and disciplinary issues. These cases can expose internal culture.
The concern raised by campaigners is that some NHS organisations appear quicker to defend reputations than to confront the substance of warnings. That concern should not be converted into a blanket finding against every trust or panel firm. Some claims will be weak. Some will be defended properly. Some settlements will be justified. Some confidentiality clauses will have legitimate scope.
But the opposite risk is also real. If whistleblowers who raise patient-safety concerns face prolonged litigation, aggressive correspondence, confidentiality pressure and financial exhaustion, the system may deter the next person from speaking up.
GOV.UK guidance states that workers who make protected whistleblowing disclosures should not be treated unfairly or lose their job because they blow the whistle. It also states that confidentiality or gagging clauses are not valid if they try to prevent a worker making a protected disclosure.
The NHS tests disputed allegations fairly, protects public funds and resolves claims on evidence.
The organisation uses legal process to delay, exhaust or silence concerns that should trigger learning and accountability.
What transparency reform should require
There are three public questions. First, can taxpayers see what is being spent and on what? Secondly, can patients and families see whether claims resolution is producing safety learning? Thirdly, can staff see that speaking up will not be met by a publicly funded war of attrition?
Granular reporting would help. NHS bodies should distinguish damages, claimant costs, defence solicitor costs, counsel fees, expert fees, local trust costs, in-house costs and settlement payments. They should also distinguish clinical negligence from employment, whistleblowing, discrimination and governance disputes.
Independent oversight would also help. An external review mechanism could examine whether NHS litigation conduct is consistent with candour, learning, value for money and fair treatment of staff and patients.
Reporting reforms
- Publish annual legal spend by trust, case type and cost category.
- Separate damages, claimant legal costs, defence solicitor costs, counsel fees and expert fees.
- Identify panel-firm spend and non-panel legal spend where disclosure is lawful.
- Report settlement outcomes and learning themes in anonymised form where appropriate.
Ethics reforms
- Require independent review of litigation strategy in serious whistleblowing and patient-safety cases.
- Limit confidentiality clauses so they cannot chill protected disclosures.
- Show how the underlying safety issue was investigated, not merely how the claim was defended.
- Assess panel-firm conduct against candour, proportionality and public-value standards.
Practical conclusion
Public money spent on legal defence is not inherently improper. The NHS is entitled to defend claims. Taxpayers are entitled to expect that unmeritorious claims will be resisted. Clinicians and managers are also entitled to fair treatment where allegations are contested.
But defensiveness is different from defence. A system that spends large sums resisting disclosure, delaying resolution or fighting whistleblowers risks becoming legally sophisticated while remaining ethically weak.
The NHS’s legal-spending problem is therefore not just financial. It is cultural. The public needs to know whether litigation spending is helping the NHS learn from harm, or helping it survive criticism without changing.